Dr. Kasi on Role of Immunotherapy in mCRC

Video

In Partnership With:

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the role of immunotherapy in the treatment of patients with metastatic colorectal cancer.

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the role of immunotherapy in the treatment of patients with metastatic colorectal cancer (mCRC).

The vast majority of patients with mCRC are left with traditional cytotoxic chemotherapy, but there is a small subset of patients who benefit from checkpoint inhibitors. These patients have tumors that are characterized by mismatch repair deficiency (dMMR) or have microsatellite instability-high (MSI-H) tumors. Patients with Lynch syndrome have also been found to derive benefit from immunotherapy, Kasi notes.

Immunotherapy is not only FDA-approved in this setting as a single agent, but the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) is also an option for these patients. By default, Kasi says, researchers should now check every patient with stage IV CRC for dMMR or MSI-H. While these patients only account for about 5% of the overall population of those with mCRC, these therapies are highly likely to have significant benefit. Notably, Kasi adds, that the trait of dMMR is known to cause a high number of mutations in the tumor, which increases the likelihood of response to immunotherapy.

Related Videos
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD